|
On April 24, 2007 GeneraMedix Inc. announced it received
approval from the U.S. Food and Drug Administration (FDA)
for its Abbreviated New Drug Applications (ANDAs) for Carboplatin
Injection. GeneraMedix will market Carboplatin
10 mg/mL
in 5 mL, 15 mL and 45 mL vials. The product is AP rated
and equivalent to the brand, Paraplatin® by Bristol-Myers
Squibb.
“The approval of Carboplatin represents a great
milestone for GeneraMedix. It is the company’s first
ANDA to receive approval and reflects our ongoing commitment
to offer generic injectable products within the U.S. market.
We are very excited and looking forward to additional product
approvals in the near future” said Ronald F. Quadrel,
President and CEO.
For product information please contact:
GeneraMedix Inc. Customer Service
1-866–GENERA–1
(1-866-436-3721)
Paraplatin® is a registered trademark of Bristol-Myers
Squibb.
|
